We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Appeals Court Upholds Allergan Eye Drug Zymar Patent Invalidation
Appeals Court Upholds Allergan Eye Drug Zymar Patent Invalidation
A federal appeals court has affirmed a lower court ruling that Allergan’s Zymar eye drop patent is invalid because the process is obvious for others to try. The decision paves the way for generic versions of the drug.